Waldencast PLC (NASDAQ:WALD) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Analysts give Waldencast a consensus rating of Hold (1 sell, 1 hold, 3 buy) with an average 12‑month target of $2.00, and several firms recently cut targets to $2 while Jefferies initiated coverage at $2 and Weiss reiterated a sell.
• WALD opened at $0.96 and sits in a 12‑month range of $0.72–$3.22, with the 50‑day moving average ($1.23) below the 200‑day ($1.68), indicating recent price weakness.
• Institutional investors own about 41.97% of the company, with recent notable buys from Milestones Administradora, Stoic Point, UBS, Geode, and Beartown Capital.

Shares of Waldencast PLC (NASDAQ:WALD - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $2.00.

WALD has been the topic of several research analyst reports. Telsey Advisory Group dropped their price objective on Waldencast from $3.00 to $2.00 and set a "market perform" rating on the stock in a research note on Monday, March 16th. Jefferies Financial Group initiated coverage on Waldencast in a research note on Wednesday, January 14th. They issued a "buy" rating and a $2.00 price objective on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Waldencast in a research note on Monday, April 20th. Finally, Canaccord Genuity Group lowered their target price on shares of Waldencast from $4.00 to $2.00 and set a "buy" rating on the stock in a report on Monday, March 16th.

Waldencast Stock Performance

Shares of NASDAQ WALD opened at $0.96 on Friday. Waldencast has a twelve month low of $0.72 and a twelve month high of $3.22. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.97 and a current ratio of 1.70. The stock's 50 day moving average price is $1.23 and its 200-day moving average price is $1.68.

Institutional Investors Weigh In On Waldencast

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Milestones Administradora de Recursos Ltda. raised its holdings in Waldencast by 10.3% during the 3rd quarter. Milestones Administradora de Recursos Ltda. now owns 2,425,677 shares of the company's stock valued at $4,803,000 after acquiring an additional 225,677 shares during the period. Stoic Point Capital Management LLC bought a new position in shares of Waldencast in the fourth quarter worth $2,628,000. UBS Group AG increased its holdings in shares of Waldencast by 466.2% in the third quarter. UBS Group AG now owns 838,536 shares of the company's stock worth $1,660,000 after purchasing an additional 690,441 shares during the period. Geode Capital Management LLC increased its holdings in shares of Waldencast by 62.2% in the second quarter. Geode Capital Management LLC now owns 586,566 shares of the company's stock worth $1,437,000 after purchasing an additional 224,905 shares during the period. Finally, Beartown Capital Management LLC bought a new position in shares of Waldencast in the fourth quarter worth $564,000. Institutional investors own 41.97% of the company's stock.

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.